Back to Journals » Therapeutics and Clinical Risk Management » Volume 17

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety

Authors Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S

Received 18 December 2020

Accepted for publication 17 March 2021

Published 7 April 2021 Volume 2021:17 Pages 285—292


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone

Gastroenterology Unit, Department of Biomedical and Clinical Sciences FBF – L.Sacco, University Hospital, Milan, Italy

Correspondence: Giovanni Maconi
Gastroenterology Unit, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli-Sacco University Hospital, University of Milan, Italy
Tel +39 02 39043164
Fax +39 02 39042232
Correspondence Email [email protected]

Abstract: Budesonide MMX is a low bioavailability corticosteroid oral once-daily formulation, which has a controlled rate of release throughout the colon, thanks to the multimatrix (MMX) formulation. It has been available for a decade in the USA and Europe for the induction of remission in patients with active, mild to moderate ulcerative colitis, particularly for those not responsive to mesalamine. The efficacy of budesonide MMX in this setting has been assessed by registrative randomized controlled trials showing a higher rate of clinical and endoscopic remission at 8 weeks compared with placebo, mostly in patients with proctosigmoiditis and left-side colitis. Since it is available in our therapeutic armamentarium, a few studies have confirmed the effectiveness of budesonide MMX also in real-life, highlighting the high rate of clinical response and remission and the high safety profile. In the present review, we summarise clinical trials and real-life results of budesonide MMX, assessing its use and predictors of response and non-response in real-life.

Keywords: budesonide MMX, ulcerative colitis, efficacy, effectiveness, safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]